Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

214 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-18

Study Completion Date

2025-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pulmonary toxicity during Hodgkin lymphoma treatment is significant for a variety of reasons, ranging from clinical care to therapeutic innovation and patient outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

NCT03200977

Lymphoma

COMPLETED

Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission

NCT04298619

Hodgkin Lymphoma High Risk Relapse

COMPLETED

Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET

NCT00188149

Hodgkin Disease

UNKNOWN PHASE4

Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

NCT06916416

Classical Hodgkin Lymphoma

NOT_YET_RECRUITING PHASE2

Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial

NCT00924131

Hodgkin's Disease Lymphoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Understanding chemotherapy-induced pulmonary issues, particularly bleomycin-induced toxicity, might enhance treatment efficacy, side effects, and quality of life for Hodgkin lymphoma patients. For Hodgkin lymphoma chemotherapy patients with pulmonary difficulties, which result in significant patient morbidity and mortality, early detection, proactive surveillance, and rapid management are required. Identifying the prevalence, risk factors, and clinical signs of pulmonary toxicity helps clinicians stratify treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

group 1

To determine treatment-induced pulmonary toxicity prevalence and risk factors in Hodgkin lymphoma patients during chemotherapy or radiation therapy.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with Hodgkin lymphoma (HL) receiving treatment.
* Patients of all ages and both genders.
* Patients with histologically confirmed HL, as per the WHO 2016 classification.
* Patients who have undergone pulmonary function testing and assessment at specified time points during their treatment course.
* Patients with complete medical records documenting treatment regimens, including chemotherapy and radiotherapy details.

Exclusion Criteria

* Patients with a diagnosis of another malignancy.
* Patients with incomplete medical records or missing data on treatment regimens and pulmonary function assessments.
* Patients with a history of significant pulmonary comorbidities, such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, or pulmonary fibrosis, before HL diagnosis.
* Patients who are unable to complete pulmonary function tests.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes